NephroCare is Fresenius Medical Care's provider business. They provide services in dialysis units in more than 40 countries across Europe, Middle East, Africa and Latin America.

The first unit opened in 1994. Today, they are treating more than 100000 patients in over 1000 dialysis units, providing about 16 million treatments per year. NephroCare hs over 31000 staff committed to delivering the highest possible quality of care.

Based on years of experience and networ-wide best practice sharing NephroCare can offer a comprehensive range of dialysis therapies individuaised to each patient's needs. These include both in center haemodialysis and perotoneal dialysis.

Vascular access for CKD patients with regards to the AVF for haemodialysis is an essential part of kidney replacement therapy. Vascular access is frequently referred to as the 'patient lifeline'. Given the vital importance of this topic NephroCare has developed numerous tools and services focusing on the management and care of vascual access. More tahn a decade of experience in NephroCare clinics has given them a high level of renal care expertise which they constantly reinvest in the NephroCare network in the formof guidelines and best practice approaches enriches and guided by NephroCare services and tools.

For these reasons, the company is strongly interested in the possible knowledge advancement of the project: "SMART - Self.Monitoring of arteriovenous fistula". They are particularly interested in the adoption of the proposed self-monitoring system for AVF to improve patient care in the follow-up phase and reduce the risk of re-hospitalization, as addressed by the project.